GLP-1 and Gallbladder Disease: Cholelithiasis Risk and Management

Written by Adam Maggio | Medically reviewed by Dr. James Whitfield, DO, FACOI

GLP-1 receptor agonists are associated with an increased risk of gallbladder disease, particularly cholelithiasis, due to rapid weight loss and altered gallbladder motility, requiring careful patient counseling and monitoring.

Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) are highly effective medications for type 2 diabetes and weight management. While their benefits in glycemic control and cardiovascular outcomes are well-established, an increased risk of gallbladder-related adverse events, particularly cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation), has emerged from clinical trials and real-world data. Understanding this risk and implementing appropriate management strategies is crucial for patient safety.

The Link Between GLP-1 RAs, Weight Loss, and Gallstones

The primary mechanism linking GLP-1 RAs to an increased risk of cholelithiasis appears to be rapid weight loss. It is well-established that significant and rapid weight loss, regardless of the method (bariatric surgery, very-low-calorie diets, or pharmacotherapy), is a major risk factor for gallstone formation [1].

Several factors contribute to this phenomenon:

Increased Biliary Cholesterol Saturation: During rapid weight loss, there is an increased mobilization of cholesterol from adipose tissue, leading to higher cholesterol secretion into bile. This can supersaturate the bile with cholesterol, promoting the formation of cholesterol gallstones [2].

Gallbladder Hypomotility: Rapid weight loss can also lead to decreased gallbladder contractility and impaired emptying. Stasis of bile in the gallbladder allows more time for cholesterol crystals to nucleate and grow into macroscopic stones [3].

Changes in Bile Acid Pool: Alterations in the enterohepatic circulation of bile acids and their composition may also play a role, though this mechanism is less clearly defined for GLP-1 RAs specifically [4].

Clinical trials for GLP-1 RAs, such as those for semaglutide and liraglutide, have consistently reported a higher incidence of cholelithiasis and cholecystitis in the active treatment arms compared to placebo. For instance, a meta-analysis of GLP-1 RA trials found a significantly increased risk of cholelithiasis (Relative Risk [RR] 1.27; 95% CI, 1.10-1.47) and cholecystitis (RR 1.36; 95% CI, 1.13-1.64) [5]. The risk appears to be dose-dependent and more pronounced with greater weight loss.

Risk Factors and Patient Identification

While rapid weight loss is a key driver, certain patient characteristics may further increase the risk of GLP-1 RA-associated gallbladder disease:

Pre-existing Gallstones: Patients with a history of gallstones or asymptomatic cholelithiasis are at a substantially higher risk of developing symptomatic disease or complications when initiating GLP-1 RAs [6].

Female Sex: Women are generally at higher risk for gallstones than men, a risk that is further amplified by pregnancy and estrogen therapy.

Age: Older age is an independent risk factor for gallstone formation.

Ethnicity: Certain ethnic groups have a higher genetic predisposition to gallstones.

High BMI: Patients with higher baseline BMI who experience significant weight loss may be at increased risk.

Management Strategies and Clinical Considerations

Given the established risk, clinicians should adopt a proactive approach to managing gallbladder disease in patients on GLP-1 RAs:

Pre-treatment Assessment: For patients with a history of symptomatic gallstones, a discussion about the risks and benefits of GLP-1 RAs, potentially alongside a surgical consultation for prophylactic cholecystectomy, may be warranted. For patients with asymptomatic gallstones, careful monitoring is advised.

Patient Counseling: All patients initiating GLP-1 RAs should be counseled about the potential symptoms of gallstones (e.g., right upper quadrant pain, nausea, vomiting, fever) and instructed to seek medical attention if they occur.

Monitoring: While routine ultrasound screening is not universally recommended for all patients, a low threshold for imaging should be maintained if symptoms suggestive of cholelithiasis or cholecystitis develop.

Treatment of Symptomatic Cholelithiasis: If symptomatic gallstones develop, management typically involves cholecystectomy, consistent with guidelines for non-GLP-1 RA-associated gallstone disease.

Ursodeoxycholic Acid (UDCA): For patients undergoing rapid weight loss (e.g., post-bariatric surgery), UDCA has been shown to reduce the risk of gallstone formation. Its role in preventing GLP-1 RA-associated gallstones is less clear but may be considered in high-risk individuals, though it is not standard practice [7].

Conclusion

GLP-1 RAs are powerful tools in the fight against type 2 diabetes and obesity, but their association with an increased risk of gallbladder disease, primarily cholelithiasis, cannot be overlooked. This risk is largely driven by rapid weight loss. By understanding the mechanisms, identifying at-risk patients, and implementing vigilant monitoring and appropriate management strategies, clinicians can maximize the therapeutic benefits of GLP-1 RAs while minimizing potential gastrointestinal complications.